Internal and Emergency Medicine

, Volume 13, Issue 3, pp 321–323 | Cite as

Pancreatic cancer: risk and preventive factors

IM - COMMENTARY
First Online:
Received:
Accepted:
  • 85 Downloads
This is a preview of subscription content, log in to check access.

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Statement of human and animal rights

This article not contain any studies with human participants or animals perfomed by any of the authors.

Informed consent

None.

References

  1. 1.
    Koh JC, Loo WM, Goh KL et al (2016) Asian consensus on the relationship between obesity and gastrointestinal and liver diseases. J Gastroenterol Hepatol 31(8):1405–1413.  https://doi.org/10.1111/jgh.13385 CrossRefPubMedGoogle Scholar
  2. 2.
    Miele L, Gasbarrini G, Giorgio V, Gasbarrini A, Grieco A (2016) Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome. Intern Emerg Med 11(1):3–10CrossRefPubMedGoogle Scholar
  3. 3.
    Chang CF, Tseng YC, Huang HH, Shih YL, Hsieh TY, Lin HH (2017) Exploring the relationship between non-alcoholic fatty liver disease and pancreatic cancer by computed tomographic survey. Intern Emerg Med.  https://doi.org/10.1007/s11739-017-1774-x Google Scholar
  4. 4.
    Włodarek D, Jerzy Podleśny JS (2007) Nonalcoholic fatty liver disease as a feature of the metabolic syndrome. Roczniki Państwowego Zakładu 58(1):129Google Scholar
  5. 5.
    Rosato V, Tavani A, Bosetti C, Pelucchi C, Talamini R, Polesel J et al (2011) Metabolic syndrome and pancreatic cancer risk: a case-control study in Italy and meta-analysis. Metabolism 60:1372–1378.  https://doi.org/10.1016/j.metabol.2011.03.005 CrossRefPubMedGoogle Scholar
  6. 6.
    Soresi M, Noto D, Cefalù AB, Martini S, Vigna GB, Fonda M, Metabolic Syndrome Study Group et al (2013) Non-alcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis society. Acta Diabetol 50(2):241–249.  https://doi.org/10.1007/s00592-012-0406-1 CrossRefPubMedGoogle Scholar
  7. 7.
    Smits MM, van Geenen EJ (2011) The clinical significance of pancreatic steatosis. Nat Rev Gastroenterol Hepatol 8(3):169–177.  https://doi.org/10.1038/nrgastro.2011.4 CrossRefPubMedGoogle Scholar
  8. 8.
    Pacifico L, Di Martino M, Anania C, Andreoli GM, Bezzi M, Catalano C et al (2015) Pancreatic fat and β-cell function in overweight/obese children with nonalcoholic fatty liver disease. World J Gastroenterol 21(15):4688–4695.  https://doi.org/10.3748/wjg.v21.i15.4688 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Després JP (2006) Lemieux I abdominal obesity and metabolic syndrome. Nature 444:881–887CrossRefPubMedGoogle Scholar
  10. 10.
    Della Corte C, Mosca A, Majo F, Lucidi V, Panera N, Giglioni E et al (2015) Nonalcoholic fatty pancreas disease and nonalcoholic fatty liver disease: more than ectopic fat. Clin Endocrinol (Oxf) 83(5):656–662.  https://doi.org/10.1111/cen.12862 CrossRefGoogle Scholar
  11. 11.
    Soresi M, Giannitrapani L, Florena AM, La Spada E, Di Gesaro V, Rappa F et al (2009) Reliability of the bright liver echo pattern in diagnosing steatosis in patients with cryptogenic and HCV-related hypertransaminasaemia. Clin Radiol 64:1181–1187CrossRefPubMedGoogle Scholar
  12. 12.
    Gullo L, Salizzoni E, Serra C, Calculli L, Bastagli L, Migliori M (2006) Can pancreatic steatosis explain the finding of pancreatic hyperenzymemia in subjects with dyslipidemia? Pancreas 33(4):351–353CrossRefPubMedGoogle Scholar
  13. 13.
    Vrieling A, Bueno-de-Mesquita HB, Boshuizen HC et al (2010) Cigarette smoking, environmental tobacco smoke exposure and pancreatic cancer risk in the European prospective investigation into cancer and nutrition. Int J Cancer 126(10):2394–2403.  https://doi.org/10.1002/ijc.24907 PubMedGoogle Scholar
  14. 14.
    Cui X, Xie Y, Chen M, Li J, Liao X, Shen J et al (2012) Statin use and risk of pancreatic cancer: a meta-analysis. Cancer Causes Control 23(7):1099–1111.  https://doi.org/10.1007/s10552-012-9979-9 CrossRefPubMedGoogle Scholar
  15. 15.
    Khurana V, Sheth A, Caldito G, Barkin JS (2007) Statins reduce the risk of pancreatic cancer in humans: a case-control study of half a million veterans. Pancreas 34:260–265CrossRefPubMedGoogle Scholar
  16. 16.
    Walker EJ, Ko AH, Holly EA, Bracci PM (2015) Statin use and risk of pancreatic cancer: results from a large, clinic-based case-control study. Cancer 121:1287–1294CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Archibugi L, Piciucchi M, Stigliano S, Valente R, Zerboni G, Barucca V et al (2017) Exclusive and combined use of statins and aspirin and the risk of pancreatic cancer: a case-control study. Sci Rep 7(1):13024.  https://doi.org/10.1038/s41598-017-13430-z CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Jiang MJ, Dai JJ, Gu DN, Huang Q, Tian L (2016) Aspirin in pancreatic cancer: chemopreventive effects and therapeutic potentials. Biochim Biophys Acta 1866(2):163–176.  https://doi.org/10.1016/j.bbcan.2016.08.002 PubMedGoogle Scholar
  19. 19.
    Zhang YP, Wan YD, Sun YL, Li J, Zhu RT (2015) Aspirin might reduce the incidence of pancreatic cancer: a meta-analysis of observational studies. Sci Rep 5:15460.  https://doi.org/10.1038/srep15460 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Polimeni L, Pastori D, Baratta F, Tozzi G, Novo M, Vicinanza R et al (2017) Spleen dimensions are inversely associated with lysosomal acid lipase activity in patients with non-alcoholic fatty liver disease. Intern Emerg Med 12(8):1159–1165CrossRefPubMedGoogle Scholar

Copyright information

© SIMI 2018

Authors and Affiliations

  • Anna Licata
    • 1
  • Giuseppe Montalto
    • 1
  • Maurizio Soresi
    • 1
  1. 1.Internal Medicine & Hepatology, DIBIMISUniversity of PalermoPalermoItaly

Personalised recommendations